Dimerix to Conduct Review of ACTION3 Statistical Assumptions
Filed with ASX · · 3 pages · English
In the deck
Earlier from Dimerix
- Dimerix Phase 3 Trial Last Patient Receives First Dose
- Appendix 4D and Half Year Financial Report
- Quarterly Appendix 4C and Activities Report
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
- DMX-200 ACTION3 Phase 3 trial completes recruitment
Later from Dimerix
- ACTION3 Statistical Review Complete
- Blinded assessment of ACTION3 statistical assumptions complete
- Dimerix Quarterly Activities Report and Appendix 4C
- Dimerix Licenses DMX200 to Everest for China and Asia Region
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix